Moreover, EGFR signalling in breast cancer cells increases c-Myc expression (Iqbal et al., 2021), HK2 activity (Jung et al., 2019), and GLUT1 plasma membrane localisation (Jung et al., 2019), while decreasing expression of TXNIP (Iqbal et al., 2021). The gene discussed is EGFR; the disease is breast carcinoma.